MedTrace Logo

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

NCT06122610 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-15

No results posted yet for this study

Summary

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.

Participants will:

* Complete two phases involving 6 visits
* Undergo additional research PET/CT, and possibly SPECT/CT scans

Conditions

Interventions

DEVICE

Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)

SPECT/CT will be performed after first cycle of Lutathera® treatment

DEVICE

Photon Emission Tomography / CT (PET/CT)

PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment

DRUG

64Cu-Dotatate

Standard of care administration of radioactive drug for PET/CT

DRUG

177Lu-Dotatate

Standard of care administration of radioactive drug for PET/CT and SPECT/CT

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Changhee Lee, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-07
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122610 on ClinicalTrials.gov